JP2019525932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019525932A5 JP2019525932A5 JP2019504000A JP2019504000A JP2019525932A5 JP 2019525932 A5 JP2019525932 A5 JP 2019525932A5 JP 2019504000 A JP2019504000 A JP 2019504000A JP 2019504000 A JP2019504000 A JP 2019504000A JP 2019525932 A5 JP2019525932 A5 JP 2019525932A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- transdermal patch
- drug reservoir
- motomeko
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 52
- -1 inorganic base compound Chemical class 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 239000010410 layer Substances 0.000 claims description 14
- 239000013543 active substance Substances 0.000 claims description 13
- 239000000853 adhesive Substances 0.000 claims description 13
- 230000001070 adhesive effect Effects 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000004821 Contact adhesive Substances 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 229920002367 Polyisobutene Polymers 0.000 claims description 4
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000013464 silicone adhesive Substances 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 229920006132 styrene block copolymer Polymers 0.000 claims description 4
- 230000037317 transdermal delivery Effects 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 150000003839 salts Chemical group 0.000 claims description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 claims description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 claims description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- 206010046555 Urinary retention Diseases 0.000 claims description 2
- 150000001278 adipic acid derivatives Chemical class 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 2
- 229960001736 buprenorphine Drugs 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 2
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 229960002428 fentanyl Drugs 0.000 claims description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002314 glycerols Chemical class 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004640 memantine Drugs 0.000 claims description 2
- 229960001344 methylphenidate Drugs 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 2
- 201000005040 opiate dependence Diseases 0.000 claims description 2
- 229960005434 oxybutynin Drugs 0.000 claims description 2
- 229920006254 polymer film Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 229940026235 propylene glycol monolaurate Drugs 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 2
- 229960001879 ropinirole Drugs 0.000 claims description 2
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 2
- 229960003179 rotigotine Drugs 0.000 claims description 2
- 150000003329 sebacic acid derivatives Chemical class 0.000 claims description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
- 239000001593 sorbitan monooleate Substances 0.000 claims description 2
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
- 229960002613 tamsulosin Drugs 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022076575A JP2022093707A (ja) | 2016-07-27 | 2022-05-06 | 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367542P | 2016-07-27 | 2016-07-27 | |
| US201662367502P | 2016-07-27 | 2016-07-27 | |
| US62/367,542 | 2016-07-27 | ||
| US62/367,502 | 2016-07-27 | ||
| US201662423133P | 2016-11-16 | 2016-11-16 | |
| US62/423,133 | 2016-11-16 | ||
| US201762444763P | 2017-01-10 | 2017-01-10 | |
| US201762444745P | 2017-01-10 | 2017-01-10 | |
| US62/444,745 | 2017-01-10 | ||
| US62/444,763 | 2017-01-10 | ||
| US201762457794P | 2017-02-10 | 2017-02-10 | |
| US62/457,794 | 2017-02-10 | ||
| US201762504391P | 2017-05-10 | 2017-05-10 | |
| US201762504408P | 2017-05-10 | 2017-05-10 | |
| US62/504,391 | 2017-05-10 | ||
| US62/504,408 | 2017-05-10 | ||
| PCT/US2017/044049 WO2018022816A1 (en) | 2016-07-27 | 2017-07-26 | Sodium bicarbonate in situ conversion driven transdermal delivery of amine drug |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076575A Division JP2022093707A (ja) | 2016-07-27 | 2022-05-06 | 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019525932A JP2019525932A (ja) | 2019-09-12 |
| JP2019525932A5 true JP2019525932A5 (enExample) | 2020-08-27 |
| JP7071330B2 JP7071330B2 (ja) | 2022-05-18 |
Family
ID=59523314
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504000A Active JP7071330B2 (ja) | 2016-07-27 | 2017-07-26 | 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達 |
| JP2019503974A Active JP7153010B2 (ja) | 2016-07-27 | 2017-07-26 | 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 |
| JP2019504001A Active JP7251033B2 (ja) | 2016-07-27 | 2017-07-26 | ドネペジル経皮送達システム |
| JP2022076575A Pending JP2022093707A (ja) | 2016-07-27 | 2022-05-06 | 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達 |
| JP2022106083A Pending JP2022121629A (ja) | 2016-07-27 | 2022-06-30 | ドネペジル経皮送達システム |
| JP2022124683A Pending JP2022140751A (ja) | 2016-07-27 | 2022-08-04 | 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503974A Active JP7153010B2 (ja) | 2016-07-27 | 2017-07-26 | 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 |
| JP2019504001A Active JP7251033B2 (ja) | 2016-07-27 | 2017-07-26 | ドネペジル経皮送達システム |
| JP2022076575A Pending JP2022093707A (ja) | 2016-07-27 | 2022-05-06 | 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達 |
| JP2022106083A Pending JP2022121629A (ja) | 2016-07-27 | 2022-06-30 | ドネペジル経皮送達システム |
| JP2022124683A Pending JP2022140751A (ja) | 2016-07-27 | 2022-08-04 | 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (13) | US9993466B2 (enExample) |
| EP (3) | EP3490558A1 (enExample) |
| JP (6) | JP7071330B2 (enExample) |
| KR (9) | KR102545643B1 (enExample) |
| CN (5) | CN109789133A (enExample) |
| AU (7) | AU2017302306A1 (enExample) |
| CA (2) | CA3032044C (enExample) |
| MX (2) | MX394249B (enExample) |
| SG (1) | SG11201900692WA (enExample) |
| WO (3) | WO2018022816A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6891118B2 (ja) | 2014-12-23 | 2021-06-18 | インテレクチュアル プロパティ アソシエイツ エルエルシーＩｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ａｓｓｏｃｉａｔｅｓ， ＬＬＣ | 経皮投与のための方法及び製剤 |
| SG11201804169QA (en) * | 2015-11-18 | 2018-06-28 | Commw Scient Ind Res Org | Rice grain with thickened aleurone |
| CN108697655B (zh) | 2015-12-30 | 2021-12-10 | 考里安公司 | 用于长期透皮施药的系统和方法 |
| CN109922796B (zh) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | 具有亲水和疏水域的粘合剂基质和治疗剂 |
| KR102508993B1 (ko) | 2016-07-27 | 2023-03-10 | 코리움, 인크. | 메만틴 경피 송달 시스템 |
| CA3032044C (en) | 2016-07-27 | 2024-10-01 | Corium, Llc | DONEPEZIL TRANSDERMAL ADMINISTRATION SYSTEM |
| CN111132669A (zh) * | 2017-07-26 | 2020-05-08 | 考里安公司 | 具有带溶剂填充孔的微孔膜的透皮递送系统 |
| WO2019055880A2 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | METHOD OF ADMINISTRATION AND TREATMENT |
| WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| KR102710072B1 (ko) * | 2018-08-31 | 2024-09-24 | 에스케이케미칼 주식회사 | 장기 투여용 리바스티그민 패취 |
| KR102823139B1 (ko) * | 2018-08-31 | 2025-06-19 | 에스케이케미칼 주식회사 | 장기 투여용 리바스티그민 패취 |
| KR102115102B1 (ko) | 2018-12-21 | 2020-05-26 | 동아에스티 주식회사 | 안정화된 도네페질 함유 경피 흡수제제 |
| KR102372630B1 (ko) * | 2019-05-15 | 2022-03-14 | 주식회사 대웅제약 | 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제 |
| US11101101B2 (en) * | 2019-05-15 | 2021-08-24 | Fei Company | Laser-based phase plate image contrast manipulation |
| CN114599349B (zh) * | 2019-10-24 | 2024-04-09 | 罗曼治疗系统股份公司 | 用于透皮施用芬戈莫德的透皮治疗系统 |
| JP7202450B2 (ja) * | 2019-11-26 | 2023-01-11 | 久光製薬株式会社 | ロピニロール含有貼付剤の粘着剤層保持力向上方法、及びロピニロール含有保持力改善貼付剤 |
| CN114829580A (zh) * | 2019-12-18 | 2022-07-29 | 先锋国际良种公司 | 用于提高植物籽粒产量的组合物和方法 |
| EP4135673A4 (en) * | 2020-04-14 | 2024-05-08 | Glanis Pharmaceuticals, Inc. | TRANSDERMAL AND/OR TOPICAL ADMINISTRATION SYSTEM COMPRISING HYDROXYCHLOROQUINE AND/OR CHLOROQUINE |
| JP2022044038A (ja) * | 2020-09-04 | 2022-03-16 | 株式会社大石膏盛堂 | ドネペジル含有経皮吸収液剤およびその製造方法 |
| CN112656778A (zh) * | 2020-12-28 | 2021-04-16 | 广东红珊瑚药业有限公司 | 一种压敏胶基质以及一种贴剂 |
| US12270039B2 (en) * | 2021-05-14 | 2025-04-08 | Board Of Trustees Of Southern Illinois University | Compositions and methods to increase oleic acid content in soybeans |
| US12270040B2 (en) * | 2021-05-27 | 2025-04-08 | Board Of Trustees Of Southern Illinois University | Soybean lines with low saturated fatty acid and high oleic acid contents |
| AU2022306570A1 (en) * | 2021-07-08 | 2024-01-18 | Monsanto Technology Llc | Novel insect inhibitory proteins |
| WO2023136966A1 (en) * | 2022-01-12 | 2023-07-20 | Inari Agriculture Technology, Inc. | Reduced height maize |
| WO2025103446A1 (zh) * | 2023-11-16 | 2025-05-22 | 宜昌人福药业有限责任公司 | 含有多奈哌齐的透皮贴剂及其制备方法 |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| NL134681C (enExample) | 1966-04-26 | |||
| US3546141A (en) | 1966-08-08 | 1970-12-08 | Mc Donnell Douglas Corp | Phosphorus-nitrogen polymers and process |
| NL7305644A (enExample) | 1972-04-20 | 1973-10-23 | ||
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| DE3572485D1 (en) | 1984-12-22 | 1989-09-28 | Thomae Gmbh Dr K | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs |
| US4797284A (en) * | 1986-03-12 | 1989-01-10 | Merck & Co., Inc. | Transdermal drug delivery system |
| US4880633A (en) | 1986-03-12 | 1989-11-14 | Merck & Co., Inc. | Transdermal drug delivery system |
| DE3634016A1 (de) | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4837027A (en) | 1987-11-09 | 1989-06-06 | Alza Corporation | Transdermal drug delivery device |
| US4781924A (en) | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
| US4849224A (en) | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
| US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
| CA2007181C (en) * | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
| DE58905637D1 (de) | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
| DE3913734C2 (de) * | 1989-04-26 | 1998-08-20 | Roehm Gmbh | Verwendung einer wäßrigen Hauthaftkleberlösung zur Herstellung einer mit Wasser leicht abwaschbaren Klebschicht |
| MY115126A (en) * | 1990-04-27 | 2003-04-30 | Seikisui Chemical Co Ltd | Percutaneously absorbable eperisone or tolperisone preparation. |
| US5252588A (en) * | 1990-04-27 | 1993-10-12 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation |
| NZ239033A (en) | 1990-07-23 | 1994-04-27 | Alza Corp | Semipermeable capsule with a hole containing a nicotine salt which reacts with water to release nicotine base |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5123900A (en) | 1991-08-16 | 1992-06-23 | Bertek, Inc. | Moisture permeable double disk |
| JPH06199659A (ja) | 1992-10-28 | 1994-07-19 | Hisamitsu Pharmaceut Co Inc | 経皮治療用装置 |
| DE4310012A1 (de) * | 1993-03-27 | 1994-09-29 | Roehm Gmbh | Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung |
| US5424077A (en) | 1993-07-13 | 1995-06-13 | Church & Dwight Co., Inc. | Co-micronized bicarbonate salt compositions |
| DE69528165T2 (de) | 1994-04-21 | 2003-05-15 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal verabreichbare grundlage und daraus hergestelltes transdermal verabreichbares arzneimittel |
| WO1996008229A2 (en) | 1994-09-14 | 1996-03-21 | Minnesota Mining And Manufacturing Company | Matrix for transdermal drug delivery |
| US5635203A (en) * | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
| AU695170B2 (en) | 1994-12-21 | 1998-08-06 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc |
| AU6032696A (en) | 1995-06-07 | 1996-12-30 | Cygnus Therapeutic Systems | Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
| DE19531342B4 (de) | 1995-08-25 | 2007-11-29 | Merz Pharma Gmbh & Co. Kgaa | Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren |
| US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| US5958919A (en) | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
| DK0934078T3 (da) | 1996-10-24 | 2003-04-14 | Alza Corp | Permeabilitetsfremmere til transdermal administrering af aktivstoffer, anordninger og fremgangsmåde til fremstilling deraf |
| CN1174031A (zh) * | 1997-04-23 | 1998-02-25 | 谢先运 | 双氯芬酸钠透皮控释贴膏 |
| US5866585A (en) | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
| US20040018241A1 (en) * | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
| JP4205778B2 (ja) * | 1998-04-17 | 2009-01-07 | 久光製薬株式会社 | 貼付製剤 |
| DE19820999A1 (de) | 1998-05-11 | 1999-11-18 | Lohmann Therapie Syst Lts | Laminat zum Aufbringen auf einen Akzeptor |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US20020192243A1 (en) * | 1999-12-16 | 2002-12-19 | Tsung-Min Hsu | Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers |
| US6562368B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
| US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
| US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| CN100340237C (zh) * | 2000-11-06 | 2007-10-03 | 株式会社三养社 | 吸水性和粘附性能改善的经皮给药系统 |
| CA2428181A1 (en) * | 2000-11-07 | 2002-05-16 | Hisamitsu Pharmaceutical Co., Inc. | Pharmaceutical preparation of percutaneous absorption type |
| JP4850346B2 (ja) * | 2001-03-15 | 2012-01-11 | 救急薬品工業株式会社 | 粘膜貼付剤 |
| US8728445B2 (en) | 2001-05-01 | 2014-05-20 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel Compositions |
| EP1427404A4 (en) | 2001-08-20 | 2005-10-26 | Maiken Nedergaard | TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS |
| EP1423100B1 (en) | 2001-09-04 | 2007-01-24 | Trommsdorff GmbH & Co.KG Arzneimittel | Plaster comprising sertaconazole for the treatment of dysfunctions and disorders of nails |
| US20040258741A1 (en) * | 2001-10-17 | 2004-12-23 | Takaaki Terahara | Percutaneous absorption preparations |
| ITMI20012827A1 (it) * | 2001-12-28 | 2003-06-28 | Fidia Farmaceutici | Formulazioni adesive transdermiche di diclofenac sodico |
| US7273619B2 (en) | 2002-01-17 | 2007-09-25 | Samyang Corporation | Transdermal composition of an antivomiting agent |
| EP2260839A3 (en) | 2002-10-24 | 2012-05-02 | Merz Pharma GmbH & Co. KGaA | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| MXPA06003316A (es) | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Formulacion farmaceutica transdermica para minimizar los residuos en la piel. |
| WO2005037157A1 (en) * | 2003-10-14 | 2005-04-28 | Dermatrends, Inc. | Enhancing transdermal administration of hydrophilic drugs |
| AR046601A1 (es) | 2003-10-22 | 2005-12-14 | Merz Pharma Gmbh & Co Kgaa | Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias |
| WO2005039651A2 (en) | 2003-10-23 | 2005-05-06 | Trans1 Inc. | Tools and tool kits for performing minimally invasive procedures on the spine |
| JP2007512338A (ja) | 2003-11-21 | 2007-05-17 | メモリー・ファーマシューティカルズ・コーポレイション | Ｌ型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法 |
| US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
| KR20070030178A (ko) | 2004-02-17 | 2007-03-15 | 트랜스오랄 파마슈티칼스, 인코포레이티드 | 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법 |
| US7670838B2 (en) | 2004-05-24 | 2010-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Coupling of excitation and neurogenesis in neural stem/progenitor cells |
| US20080038328A1 (en) | 2004-05-28 | 2008-02-14 | Naruhito Higo | Pasting Preparation |
| TW200616608A (en) | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| CA2583340C (en) | 2004-10-08 | 2015-09-08 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery device including an occlusive backing |
| EP1661560B1 (en) | 2004-11-22 | 2008-11-05 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal patch comprising a melting point lowering agent |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| HRP20090676T1 (hr) | 2005-01-11 | 2010-01-31 | Teva Pharmaceutical Fine Chemicals S.R.L. | Postupak dobivanja 1-amino-3,5-dimetiladamantan-hidroklorida |
| WO2006082728A1 (ja) * | 2005-02-04 | 2006-08-10 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収貼付剤 |
| US20060188558A1 (en) | 2005-02-18 | 2006-08-24 | Mylan Technologies, Inc. | Transdermal systems having control delivery system |
| BRPI0607017B8 (pt) | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
| US7888422B2 (en) | 2005-11-09 | 2011-02-15 | Mylan Technologies Inc. | Long-wearing removable pressure sensitive adhesive |
| US20070237916A1 (en) * | 2006-03-28 | 2007-10-11 | Torben Rasmussen | Multilayer film free of halogens which is impermeable to aroma compounds |
| CN1895242B (zh) * | 2006-04-13 | 2011-08-31 | 沈阳药科大学 | 双氯芬酸盐的透皮贴剂及制备方法 |
| IL175338A0 (en) | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
| MY149152A (en) | 2006-05-08 | 2013-07-15 | Teikoku Seiyaku Kk | Percutaneous absorption preparations of antimentia drugs |
| JP5097359B2 (ja) * | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | ドネペジル経皮吸収型製剤 |
| TW200815045A (en) | 2006-06-29 | 2008-04-01 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of ropinirole and methods of use thereof |
| US9248104B2 (en) | 2006-08-17 | 2016-02-02 | Core Tech Solutions, Inc. | Transdermal methods and systems for treating Alzheimer's disease |
| US20080107719A1 (en) | 2006-11-08 | 2008-05-08 | Sukhon Likitlersuang | Transdermal drug delivery system |
| EP2098233A4 (en) | 2006-12-01 | 2012-03-21 | Nitto Denko Corp | PREPARATION OF SKIN ADHESIVE COMPRISING DERESEPZIL STABILIZED |
| KR101408488B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법 |
| CN101605545B (zh) | 2006-12-01 | 2011-10-05 | 日东电工株式会社 | 含有稳定化的多奈哌齐的贴剂 |
| JP5403948B2 (ja) | 2007-06-07 | 2014-01-29 | 久光製薬株式会社 | メマンチン含有経皮吸収製剤 |
| AU2008275101B2 (en) | 2007-07-10 | 2014-08-21 | Agile Therapeutics, Inc. | Dermal delivery device with in situ seal |
| US9017301B2 (en) * | 2007-09-04 | 2015-04-28 | Mylan Technologies, Inc. | Transdermal drug delivery systems comprising a coated release liner |
| JP2009203213A (ja) * | 2008-02-28 | 2009-09-10 | Kosumedei Seiyaku Kk | 経皮吸収医薬組成物 |
| DE102008013701A1 (de) * | 2008-03-11 | 2009-09-17 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System mit stabilisierter Membran |
| KR101454362B1 (ko) | 2008-03-24 | 2014-10-23 | 아이큐어 주식회사 | 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제 |
| EP2111857A1 (de) | 2008-04-25 | 2009-10-28 | Acino AG | Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon |
| US20090291127A1 (en) | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| PE20100371A1 (es) | 2008-10-31 | 2010-06-01 | Lexicon Pharmaceuticals Inc | Agonistas del receptor s1p para el tratamiento de malaria cerebral |
| US20100178037A1 (en) | 2009-01-12 | 2010-07-15 | Te-Wei Chen | Display apparatus, video generation apparatus, and method thereof |
| WO2010083035A2 (en) * | 2009-01-14 | 2010-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
| KR101725832B1 (ko) | 2009-05-01 | 2017-04-11 | 히사미쓰 세이야꾸 가부시키가이샤 | 경피 흡수형 제제 |
| WO2011034323A2 (en) | 2009-09-16 | 2011-03-24 | Samyang Corporation | Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system |
| KR101734602B1 (ko) | 2009-10-21 | 2017-05-11 | 데이고꾸세이약꾸가부시끼가이샤 | 도네페질 함유 경피 흡수형 제제 |
| CN102048678A (zh) * | 2009-10-30 | 2011-05-11 | 北京隆旗生物科技有限公司 | 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用 |
| GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
| JP2012236773A (ja) | 2009-12-16 | 2012-12-06 | Goto Takeshi | 抗認知症薬物の経皮吸収製剤 |
| EP2519225B1 (en) | 2009-12-30 | 2015-03-25 | Novartis AG | Melt extruded nicotine thin strips |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| JP5615898B2 (ja) | 2010-02-24 | 2014-10-29 | 久光製薬株式会社 | 貼付剤 |
| US20110244023A1 (en) * | 2010-03-30 | 2011-10-06 | Phosphagenics Limited | Transdermal delivery patch |
| WO2011136288A1 (ja) | 2010-04-28 | 2011-11-03 | 久光製薬株式会社 | ドネペジル含有経皮吸収製剤 |
| WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
| DE102010024105A1 (de) | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| US20140370076A1 (en) | 2010-06-30 | 2014-12-18 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing donepezil |
| NZ605352A (en) * | 2010-06-30 | 2013-10-25 | Nal Pharmaceuticals Ltd | Process for producing glycosaminoglycans |
| AU2011282683B2 (en) | 2010-07-29 | 2016-12-22 | Allergan, Inc. | Preservative free brimonidine and timolol solutions |
| AU2011316565A1 (en) | 2010-10-12 | 2013-05-02 | Cerecor Inc. | Antitussive compositions comprising memantine |
| JP5699554B2 (ja) | 2010-11-11 | 2015-04-15 | 富士通株式会社 | ベクトル処理回路、命令発行制御方法、及びプロセッサシステム |
| CA2815898C (en) | 2010-11-17 | 2018-12-18 | Hexal Ag | Transdermal therapeutic system comprising buprenorphine |
| WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
| EP2658576A1 (en) * | 2010-12-29 | 2013-11-06 | Pharmafilm S.R.L. | Medicated patch for improved transdermal permeation of diclofenac diethylammonium |
| TWI433904B (zh) | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | 多奈哌齊經皮貼片 |
| CN102775476B (zh) | 2011-05-12 | 2015-01-07 | 上海天伟生物制药有限公司 | 一种米卡芬净钠盐的制备方法 |
| US8673338B2 (en) | 2011-07-29 | 2014-03-18 | Massachusetts Eye And Ear Infirmary | Methods of delivering pharmaceutical agents |
| JP5808214B2 (ja) | 2011-09-30 | 2015-11-10 | 株式会社トクヤマ | 貼付剤 |
| KR101239150B1 (ko) | 2012-02-28 | 2013-03-06 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
| US9408802B1 (en) * | 2012-03-22 | 2016-08-09 | Prosolus, Inc. | Seven day drug in adhesive transdermal delivery |
| US9145907B2 (en) | 2012-08-28 | 2015-09-29 | Hsiutao Liang | Pipe connector |
| US20140256690A1 (en) | 2013-03-08 | 2014-09-11 | Agile Therapeutics, Inc. | Contraceptive method |
| WO2014174564A1 (ja) | 2013-04-22 | 2014-10-30 | 祐徳薬品工業株式会社 | メマンチン含有経皮吸収型貼付製剤 |
| JP5415645B1 (ja) * | 2013-06-28 | 2014-02-12 | 久光製薬株式会社 | 貼付剤の製造方法、貼付剤及び包装体 |
| WO2015031552A1 (en) * | 2013-08-30 | 2015-03-05 | 3M Innovative Properties Company | Estradiol containing transdermal drug delivery systems and compositions |
| KR101827980B1 (ko) | 2013-10-07 | 2018-02-13 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법 |
| JP6401257B2 (ja) * | 2013-10-11 | 2018-10-10 | テイコク ファーマ ユーエスエー インコーポレーテッド | 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法 |
| EP3069712B1 (en) | 2013-11-17 | 2020-09-23 | MEDRx Co., Ltd. | Transdermal colloidal solution agent |
| KR101485822B1 (ko) | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | 도네페질 또는 그의 염을 함유하는 경피흡수제제 |
| JP2015151370A (ja) * | 2014-02-14 | 2015-08-24 | 日東電工株式会社 | 貼付製剤 |
| WO2015200472A1 (en) | 2014-06-24 | 2015-12-30 | KAT Transdermals LLC | Transdermal delivery system |
| US10071090B2 (en) * | 2014-07-18 | 2018-09-11 | Buzzz Pharmaceuticals Limited | Oxymorphone transdermal patch |
| CN106687138B (zh) | 2014-09-03 | 2021-10-15 | 日东电工株式会社 | 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物 |
| WO2016046675A1 (en) | 2014-09-28 | 2016-03-31 | Mohan M Alapati | Compositions and methods for the treatment of neurological diseases |
| WO2016099198A1 (ko) | 2014-12-18 | 2016-06-23 | 아이큐어 주식회사 | 도네페질을 유효성분으로 함유하는 경피흡수제제 |
| AU2015380301B2 (en) | 2015-01-28 | 2020-04-23 | Dnx Biotech, Llc | Compositions and methods of using a soluble TNF-alpha receptor modified for increased half-life |
| US20180185298A1 (en) | 2015-06-22 | 2018-07-05 | Corium International, Inc. | Transdermal Adhesive Composition Comprising A Poorly Soluble Therapeutic Agent |
| JP6462880B2 (ja) | 2015-07-27 | 2019-01-30 | 久光製薬株式会社 | アセナピン含有貼付剤の製造方法 |
| CN108697655B (zh) * | 2015-12-30 | 2021-12-10 | 考里安公司 | 用于长期透皮施药的系统和方法 |
| CN105693556A (zh) | 2016-03-01 | 2016-06-22 | 巴斯特医药科技（常州）有限公司 | 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片 |
| CN109922796B (zh) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | 具有亲水和疏水域的粘合剂基质和治疗剂 |
| CA3032044C (en) | 2016-07-27 | 2024-10-01 | Corium, Llc | DONEPEZIL TRANSDERMAL ADMINISTRATION SYSTEM |
| KR102508993B1 (ko) | 2016-07-27 | 2023-03-10 | 코리움, 인크. | 메만틴 경피 송달 시스템 |
| WO2018022814A1 (en) * | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
| CN111132669A (zh) | 2017-07-26 | 2020-05-08 | 考里安公司 | 具有带溶剂填充孔的微孔膜的透皮递送系统 |
-
2017
- 2017-07-26 CA CA3032044A patent/CA3032044C/en active Active
- 2017-07-26 EP EP17749059.6A patent/EP3490558A1/en active Pending
- 2017-07-26 KR KR1020227018749A patent/KR102545643B1/ko active Active
- 2017-07-26 US US15/660,943 patent/US9993466B2/en active Active
- 2017-07-26 US US15/660,939 patent/US10300025B2/en active Active
- 2017-07-26 JP JP2019504000A patent/JP7071330B2/ja active Active
- 2017-07-26 EP EP17749058.8A patent/EP3490540A1/en active Pending
- 2017-07-26 CN CN201780059393.5A patent/CN109789133A/zh active Pending
- 2017-07-26 KR KR1020197005331A patent/KR102406536B1/ko active Active
- 2017-07-26 JP JP2019503974A patent/JP7153010B2/ja active Active
- 2017-07-26 KR KR1020237023326A patent/KR20230109782A/ko not_active Withdrawn
- 2017-07-26 KR KR1020237020235A patent/KR20230097203A/ko not_active Ceased
- 2017-07-26 JP JP2019504001A patent/JP7251033B2/ja active Active
- 2017-07-26 AU AU2017302306A patent/AU2017302306A1/en not_active Abandoned
- 2017-07-26 EP EP17749568.6A patent/EP3490541B1/en active Active
- 2017-07-26 KR KR1020227018732A patent/KR102545649B1/ko active Active
- 2017-07-26 US US15/660,935 patent/US20180028463A1/en not_active Abandoned
- 2017-07-26 KR KR1020197005739A patent/KR102406528B1/ko active Active
- 2017-07-26 AU AU2017301928A patent/AU2017301928B2/en active Active
- 2017-07-26 KR KR1020237020230A patent/KR20230098349A/ko not_active Ceased
- 2017-07-26 KR KR1020227018748A patent/KR102555208B1/ko active Active
- 2017-07-26 WO PCT/US2017/044049 patent/WO2018022816A1/en not_active Ceased
- 2017-07-26 CA CA3031945A patent/CA3031945C/en active Active
- 2017-07-26 CN CN202211676624.6A patent/CN116270551A/zh active Pending
- 2017-07-26 CN CN201780059417.7A patent/CN109789105B/zh active Active
- 2017-07-26 WO PCT/US2017/044050 patent/WO2018022817A1/en not_active Ceased
- 2017-07-26 CN CN202310658352.5A patent/CN116966166A/zh active Pending
- 2017-07-26 MX MX2019001103A patent/MX394249B/es unknown
- 2017-07-26 AU AU2017302307A patent/AU2017302307A1/en not_active Abandoned
- 2017-07-26 US US15/660,924 patent/US20180028663A1/en not_active Abandoned
- 2017-07-26 CN CN201780059437.4A patent/CN109789106B/zh active Active
- 2017-07-26 KR KR1020197005737A patent/KR102406482B1/ko active Active
- 2017-07-26 SG SG11201900692WA patent/SG11201900692WA/en unknown
- 2017-07-26 WO PCT/US2017/044048 patent/WO2018022815A2/en not_active Ceased
-
2018
- 2018-04-19 US US15/957,858 patent/US10307379B2/en active Active
-
2019
- 2019-01-25 MX MX2022006681A patent/MX2022006681A/es unknown
- 2019-04-23 US US16/392,544 patent/US20190247321A1/en not_active Abandoned
- 2019-04-23 US US16/392,513 patent/US11103463B2/en active Active
-
2020
- 2020-10-07 US US17/065,302 patent/US20210015761A1/en not_active Abandoned
-
2021
- 2021-08-05 US US17/395,359 patent/US20220016045A1/en not_active Abandoned
-
2022
- 2022-05-06 JP JP2022076575A patent/JP2022093707A/ja active Pending
- 2022-06-30 JP JP2022106083A patent/JP2022121629A/ja active Pending
- 2022-08-04 JP JP2022124683A patent/JP2022140751A/ja active Pending
-
2023
- 2023-06-09 AU AU2023203618A patent/AU2023203618B2/en active Active
- 2023-06-09 AU AU2023203616A patent/AU2023203616A1/en not_active Abandoned
- 2023-06-20 US US18/337,974 patent/US20240156747A1/en not_active Abandoned
- 2023-07-03 AU AU2023204240A patent/AU2023204240A1/en not_active Abandoned
-
2024
- 2024-10-22 US US18/922,900 patent/US20250325496A1/en active Pending
-
2025
- 2025-03-20 US US19/085,857 patent/US20250375395A1/en active Pending
- 2025-05-30 US US19/223,763 patent/US20250375396A1/en active Pending
- 2025-07-08 AU AU2025205205A patent/AU2025205205A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019525932A5 (enExample) | ||
| JP7153010B2 (ja) | 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 | |
| JP2019523268A5 (enExample) | ||
| TWI502037B (zh) | Percutaneous absorption type preparation | |
| JP2017137363A (ja) | 貼付剤 | |
| JP2010529116A (ja) | マトリックス型経皮投与剤およびその製造方法 | |
| TW201206506A (en) | Propynylaminoindan transdermal compositions | |
| TW200902090A (en) | Transdermal administration device for bisoprolol | |
| JP6832287B2 (ja) | ２層の接着層を含むオーバーテープを用いる経皮治療システム | |
| CN101411694A (zh) | 贴片制剂 | |
| TW201422258A (zh) | 貼附劑 | |
| TWI845498B (zh) | 含有矽酸鈣之丙烯酸系貼附劑 | |
| WO2023025195A1 (zh) | 阿哌沙班透皮贴剂及其制备方法 | |
| TW200906405A (en) | Skin adhesive preparation comprising stabilized donepezil | |
| TW202045144A (zh) | 抑制丙烯酸系貼附劑的冷流之方法 | |
| TWI626953B (zh) | Percutaneous absorption preparation | |
| JP2024096497A (ja) | 水性貼付剤 | |
| JP5155128B2 (ja) | メチルフェニデート貼付製剤 | |
| JP6864968B2 (ja) | 貼付剤 | |
| JP2002029969A (ja) | 経皮吸収製剤 |